MedTrace Logo

Depression in Alzheimer's Disease-2

NCT00086138 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2017-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Conditions

Interventions

DRUG

Sertraline (Zoloft)

Sertraline: range of 25 to 125 mg per day for 24 weeks

DRUG

Placebo

Placebo designed to mimic sertraline taken daily for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Constantine G. Lyketsos, MD, MHS · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086138 on ClinicalTrials.gov